AssetMark Inc’s Madrigal Pharmaceuticals MDGL Stock Holding History

AssetMark Inc’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.02M	Sell	4,004 -177	-4%	-$93.5K	﹤0.01%	952
2026 Q2	$2.24M	Sell	4,181 -208	-5%	-$107K	﹤0.01%	925
2026 Q1	$2.3M	Sell	4,389 -421	-9%	-$201K	﹤0.01%	855
2025 Q4	$2.8M	Sell	4,810 -248	-5%	-$127K	0.01%	776
2025 Q3	$2.32M	Buy	5,058 +160	+3%	+$59.7K	0.01%	779
2025 Q2	$1.48M	Sell	4,898 -285	-5%	-$84.9K	﹤0.01%	837
2025 Q1	$1.72M	Buy	5,183 +1,003	+24%	+$330K	﹤0.01%	756
2024 Q4	$1.29M	Buy	4,180 +238	+6%	+$66.9K	﹤0.01%	801
2024 Q3	$837K	Buy	3,942 +303	+8%	+$77.5K	﹤0.01%	813
2024 Q2	$1.02M	Buy	+3,639	New	+$866K	﹤0.01%	759

Other funds holding MDGL

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

AssetMark Inc's MDGL Position: Q3 2026 in Review

AssetMark Inc reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.2% in Q3 2026, selling an estimated $93.5K and leaving 4,004 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #952.

AssetMark Inc first reported a position in MDGL in Q2 2024 and has held it in 10 quarters since. The position peaked at $2.8M in Q4 2025. 155 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

AssetMark Inc held 4,004 shares of Madrigal Pharmaceuticals worth $2.02M as of Q3 2026.
AssetMark Inc sold 177 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $93.5K.
Madrigal Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #952 holding.
AssetMark Inc first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
AssetMark Inc's Madrigal Pharmaceuticals position peaked at $2.8M in Q4 2025.
155 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.